Lokelma (Sodium Zirconium Cyclosilicate) Dosing and Management
For chronic hyperkalaemia in patients on RAASi therapy, initiate Lokelma at 10 g three times daily for 48 hours, then transition to 10 g once daily for maintenance, with dose adjustments based on serum potassium monitoring at weekly intervals. 1
Initial Treatment Phase (Correction Phase)
Start with 10 g orally three times daily for up to 48 hours to rapidly correct hyperkalaemia 1. This dosing achieves:
- Significant potassium reduction within 1 hour of the first dose 2
- Mean reduction of approximately 1.0-1.3 mEq/L within 48 hours 2, 3
- Achievement of normokalaemia (3.5-5.0 mEq/L) in 82-100% of patients within 24-72 hours 4
Administration Instructions
- Mix entire packet contents in approximately 3 tablespoons of water 1
- Stir well and drink immediately
- Separate from other oral medications by at least 2 hours before or after Lokelma 1
Maintenance Phase
After achieving normokalaemia, transition to 10 g once daily 1. This is the FDA-recommended starting maintenance dose that balances efficacy with safety.
Dose Titration Schedule
Monitor serum potassium and adjust at intervals of 1 week or longer in 5 g increments 1:
- If potassium remains elevated (>5.0 mEq/L): Increase to 15 g once daily (maximum dose)
- If potassium is in target range (3.5-5.0 mEq/L): Continue current dose
- If potassium drops below target (<3.5 mEq/L): Decrease to 5 g once daily or 5 g every other day, or discontinue temporarily
The maintenance dose range is 5 g every other day to 15 g daily 2, 1.
Monitoring Strategy
Initial Monitoring
- Check serum potassium after 48 hours (end of correction phase) to confirm normokalaemia before transitioning to maintenance dosing
- Reassess 1 week after starting maintenance therapy 1
- Continue weekly monitoring after each dose adjustment 1
Long-term Monitoring
Once stable on maintenance therapy, follow guideline-directed monitoring appropriate for the underlying condition (CKD, heart failure) 5. For patients with CKD or heart failure on RAASi:
- Monitor potassium 2-4 times yearly 5
- Check within 1 week after any RAASi dose escalation 2
- Monitor renal function and electrolytes concurrently 2
Critical Management Considerations
RAASi Continuation
Do not discontinue or down-titrate RAASi therapy when initiating Lokelma 2, 5. The primary goal is maintaining optimal RAASi dosing while controlling potassium:
- Continue RAASi at current doses during Lokelma initiation 2
- Consider up-titrating RAASi to guideline-recommended target doses once normokalaemia is achieved 2
- Evidence shows Lokelma enables RAASi optimization without increasing hyperkalaemia risk 6, 7
Common Pitfalls to Avoid
Hypokalemia risk with lower baseline potassium: Exercise caution when baseline potassium is 5.0-5.5 mEq/L 3. In these patients:
- Consider starting with 5 g three times daily instead of 10 g three times daily
- Monitor more frequently during the first 48 hours
- 25% of patients may develop potassium <4.0 mEq/L with standard loading doses 3
Edema monitoring: Each 5 g dose contains approximately 400 mg sodium 1. Monitor for:
- Signs of fluid overload, particularly in heart failure patients
- Dose-dependent edema (more common with 15 g daily dosing) 2
- Need for diuretic adjustment 1
Gastrointestinal contraindications: Avoid in patients with severe constipation, bowel obstruction, or impaction 1. Lokelma has not been studied in these populations and may worsen gastrointestinal conditions.
Duration of Therapy
Plan for indefinite treatment in patients with chronic conditions (CKD, heart failure) causing persistent hyperkalaemia 5. Discontinuation should only occur if:
- The underlying cause of hyperkalaemia is reversed
- Persistent hypokalemia develops despite dose reduction
- RAASi therapy is permanently discontinued (though this is generally not recommended)
Safety Profile
Lokelma demonstrates a favorable safety profile with no serious adverse events reported in randomized trials 2. The most common adverse events are:
- Hypokalemia (dose-related)
- Mild to moderate edema (dose-dependent, more common at 15 g daily) 2
- Gastrointestinal symptoms (constipation, diarrhea, nausea) - generally mild 2
Lokelma has significant advantages over older potassium binders: rapid onset (1 hour vs 7+ hours for patiromer), high selectivity for potassium, and no association with serious gastrointestinal injury unlike sodium polystyrene sulfonate 2.